Medicenna Advances Key Programs with Upcoming Data Presentations and Regulatory Discussions
Event summary
- Medicenna to present updated MDNA11 clinical results at an upcoming medical conference, with Phase 1/2 ABILITY-1 study enrollment on track for Q3 2026 completion.
- New bizaxofusp data for recurrent glioblastoma to be presented orally at a medical conference; FDA Fast Track and Orphan Drug designations already secured.
- Company ended Q1 fiscal 2027 with $5.7M in cash, down from $6.3M last quarter, but expects financing to extend runway into Q2 2027.
- Planning underway for IND submission and Phase 1 trial of MDNA113, a first-in-class anti-PD-1-IL-2 bifunctional Superkine, in 2027.
The big picture
Medicenna is positioning itself for a data-rich second half of 2026, with key presentations and regulatory discussions that could accelerate its lead programs. The company’s focus on IL-2 Superkines aligns with broader industry trends toward targeted immuno-oncology therapies, though execution risks remain high given the competitive landscape in cancer immunotherapy.
What we're watching
- Regulatory Pathway
- Whether Medicenna can secure an expedited registrational development path for MDNA11 following end-of-Phase 1 discussions with the FDA.
- Clinical Momentum
- The pace at which NEO-CYT study enrollment progresses and preliminary data emerges in Q4 2026.
- Financial Liquidity
- How the completion of the Sorbie Transaction impacts Medicenna’s cash runway beyond Q2 2027.
Related topics